Stock RJF LABORATORIO REIG JOFRE, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Laboratorio Reig Jofre, S.A.

Equities

RJF

ES0165359029

Pharmaceuticals

Market Closed - BME
Other stock markets
 11:35:10 2024-04-30 am EDT 		5-day change 1st Jan Change
2.49 EUR -0.80% Intraday chart for Laboratorio Reig Jofre, S.A. -1.19% +10.67%
Mar. 13 Transcript : Laboratorio Reig Jofre, S.A., 2023 Earnings Call, Mar 13, 2024
Feb. 29 Laboratorio Reig Jofre, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 147.8 190.9 335.4 250.8 170.1 177.3
Enterprise Value (EV) 1 165.5 237.5 381.3 312.9 224.9 225.2
P/E ratio 16.1 x 36.3 x 57 x 49.2 x 21.9 x 18.8 x
Yield - - 1.03% 1.23% 1.83% -
Capitalization / Revenue 0.8 x 0.93 x 1.44 x 1.05 x 0.62 x 0.56 x
EV / Revenue 0.89 x 1.15 x 1.63 x 1.3 x 0.82 x 0.71 x
EV / EBITDA 10.8 x 11.4 x 18.8 x 15.4 x 9.97 x 7.96 x
EV / FCF -21.6 x -44.2 x 29.3 x -18.1 x 25 x 49.2 x
FCF Yield -4.62% -2.26% 3.42% -5.52% 3.99% 2.03%
Price to Book 0.99 x 1.07 x 1.81 x 1.33 x 0.87 x 0.87 x
Nbr of stocks (in thousands) 64,837 75,770 76,412 76,935 77,694 78,802
Reference price 2 2.280 2.520 4.390 3.260 2.190 2.250
Announcement Date 3/1/19 3/2/20 2/26/21 2/28/22 2/28/23 2/29/24
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 185.3 205.8 233.8 239.9 274.2 318
EBITDA 1 15.29 20.79 20.32 20.36 22.56 28.3
EBIT 1 8.788 8.843 9.566 9.276 9.373 11.99
Operating Margin 4.74% 4.3% 4.09% 3.87% 3.42% 3.77%
Earnings before Tax (EBT) 1 9.483 5.303 6.426 5.793 8.764 10.5
Net income 1 9.266 4.942 5.672 5.092 8.107 9.407
Net margin 5% 2.4% 2.43% 2.12% 2.96% 2.96%
EPS 2 0.1419 0.0693 0.0770 0.0662 0.1000 0.1194
Free Cash Flow 1 -7.652 -5.373 13.02 -17.28 8.98 4.577
FCF margin -4.13% -2.61% 5.57% -7.2% 3.27% 1.44%
FCF Conversion (EBITDA) - - 64.09% - 39.8% 16.17%
FCF Conversion (Net income) - - 229.6% - 110.77% 48.65%
Dividend per Share - - 0.0450 0.0400 0.0400 -
Announcement Date 3/1/19 3/2/20 2/26/21 2/28/22 2/28/23 2/29/24
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 17.6 46.6 45.9 62.1 54.8 47.9
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.154 x 2.24 x 2.257 x 3.048 x 2.427 x 1.693 x
Free Cash Flow 1 -7.65 -5.37 13 -17.3 8.98 4.58
ROE (net income / shareholders' equity) 6.35% 3.01% 3.13% 2.72% 4.23% 4.71%
ROA (Net income/ Total Assets) 2.6% 2.07% 1.9% 1.81% 1.81% 2.3%
Assets 1 356.8 238.4 299.2 282 447.1 409
Book Value Per Share 2 2.310 2.350 2.420 2.460 2.510 2.590
Cash Flow per Share 2 0.1300 0.1300 0.1500 0.0700 0.0800 0.0700
Capex 1 15.9 5.85 4.21 19.2 10.9 12.5
Capex / Sales 8.56% 2.84% 1.8% 8.01% 3.99% 3.92%
Announcement Date 3/1/19 3/2/20 2/26/21 2/28/22 2/28/23 2/29/24
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
LABORATORIO REIG JOFRE, S.A. Stock Laboratorio Reig Jofre, S.A.
+10.67% 210M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+34.00% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.29% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.75% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.53% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.95% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.79% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-4.89% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. RJF Stock
  4. Financials Laboratorio Reig Jofre, S.A.